Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202551 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety Study of ADS-5102 in PD Patients With LID
A Phase 3 study of Parkinsons Disease (PD) and Dyskinesia, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
- 20
- Study locations
NCT02202551 is a Phase 3 study of Parkinsons Disease (PD) and Dyskinesia that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 223 participants, above the 108-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (106% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02202551, a Phase 3 study of Parkinsons Disease (PD) and Dyskinesia, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).
Conditions Studied
Interventions
- DRUG ADS-5102
Study Locations (20)
California
- - Fountain Valley
- - Pasadena
- - Reseda
- - Sacramento
- - Sunnyvale
- - Torrance
- - Ventura
Florida
- - Boca Raton
- - Gainesville
- - Jacksonville
- - Naples
- - Port Charlotte
- - Sunrise
- - Tampa
Arizona
- - Phoenix
- - Scottsdale
- - Sun City
Alabama
- - Birmingham
Colorado
- - Aurora
Connecticut
- - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02202551
The ClinicalTrials.gov registry entry for NCT02202551 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 19 other Parkinsons Disease (PD) trials with a reported enrollment target (106% higher). The listed sponsor is Adamas Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Parkinsons Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which ADS-5102 is the first listed.
NCT02202551 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02202551 about?
NCT02202551 is a clinical study titled "Open-Label Safety Study of ADS-5102 in PD Patients With LID". This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).
What is the current status of trial NCT02202551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2014-07. Estimated completion is 2018-02.
What conditions does trial NCT02202551 study?
This clinical trial studies the following conditions: Parkinsons Disease (PD), Dyskinesia, Levodopa Induced Dyskinesia (LID).
What interventions are being tested in trial NCT02202551?
The interventions under investigation include: ADS-5102 (DRUG).
Who is sponsoring clinical trial NCT02202551?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02202551 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinsons Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
RECRUITING · Phase 3
-
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
COMPLETED · Phase 3
-
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
RECRUITING · NA
-
A Study of NE3107 in Early Parkinson's
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.